Administration of ubiquitin-activating enzyme UBA1 inhibitor PYR-41 attenuates angiotensin II-induced cardiac remodeling in mice.
Sign Up to like & getrecommendations! Published in 2018 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2018.09.100
Abstract: Pathological cardiac hypertrophy is the main risk factor for heart diseases. The ubiquitin-proteasome system (UPS) is the major intracellular protein degradation system involved in the development of cardiac hypertrophic remodeling. Ubiquitin-activating enzyme E1, a key… read more here.
Keywords: pyr; hypertrophic remodeling; inhibitor pyr; uba1 inhibitor ... See more keywords
Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0167-0
Abstract: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme in the… read more here.
Keywords: tak 243; myeloid leukemia; uba1 inhibitor; acute myeloid ... See more keywords